Affiliation:
1. Section for Breast Cancer Screening, Cancer Registry of Norway, Oslo, Norway
2. Department of Radiology, Vestfold Hospital, Tønsberg, Norway
3. Department of Radiology, Stavanger University Hospital, Stavanger, Norway
4. Department of Radiology, Vestre Viken Hospital Trust, Drammen, Norway
5. Department of Health and Care Sciences, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway
Abstract
Objective Irregular attendance in breast cancer screening has been associated with higher breast cancer mortality compared to regular attendance. Early performance measures of a screening program following regular versus irregular screening attendance have been less studied. We aimed to investigate early performance measures following regular versus irregular screening attendance. Methods We used information from 3,302,396 screening examinations from the Cancer Registry of Norway. Examinations were classified as regular or irregular. Regular was defined as an examination 2 years ± 6 months after the prior examination, and irregular examination >2 years and 6 months after prior examination. Performance measures included recall, biopsy, screen-detected and interval cancer, positive predictive values, and histopathological tumor characteristics. Results Recall rate was 2.4% (72,429/3,070,068) for regular and 3.5% (8217/232,328) for irregular examinations. The biopsy rate was 1.0% (29,197/3,070,068) for regular and 1.7% (3825/232,328) for irregular examinations, while the rate of screen-detected cancers 0.51% (15,664/3,070,068) versus 0.86% (2003/232,328), respectively. The adjusted odds ratio was 1.53 (95% CI: 1.49–1.56) for recall, 1.73 (95% CI: 1.68–1.80) for biopsy, and 1.68 (95% CI: 1.60–1.76) for screen-detected cancer after irregular examinations compared to regular examinations. The proportion of lymph node-positive tumors was 20.1% (2553/12,719) for regular and 25.6% (426/1662) for irregular examinations. Conclusion Irregular attendance was linked to higher rates of recall, needle biopsies, and cancer detection. Cancers detected after irregular examinations had less favorable histopathological tumor characteristics compared to cancers detected after regular examinations. Women should be encouraged to attend screening when invited to avoid delays in diagnosis.
Subject
Public Health, Environmental and Occupational Health,Health Policy
Reference31 articles.
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. European Commission Initiative on Breast Cancer. European guidelines on breast cancer screening and diagnosis 2021 [cited 2021 30.05.23]. Available from: https://healthcare-quality.jrc.ec.europa.eu/ecibc/european-breast-cancer-guidelines.
3. Breast-Cancer Screening — Viewpoint of the IARC Working Group
4. The potential of breast cancer screening in Europe
5. Bjørnson EW, Holen ÅS, Sagstad S, et al. BreastScreen Norway: 25 years of organized screening Oslo: Cancer Registry of Norway; 2022 [09.05.2023]. Available from: https://www.kreftregisteret.no/Generelt/Rapporter/Mammografiprogrammet/25-arsrapport-mammografiprogrammet/.